Amit Garg brings a multicultural perspective from being raised in Brazil by Indian parents and speaks three languages natively, which he applies to cross-border investing, plus he has an unusual combination of computer science, biomedical informatics from Stanford, and Harvard MBA training that he uses to invest in AI-heavy healthcare and enterprise startups. He runs a highly disciplined, memo-driven investment process where he reviews around 2,000 companies per year and writes detailed memos for roughly 25 serious deals, and he's committed to transparent founder education through detailed LinkedIn essays on tactical topics like choosing corporate lead investors and entering the US market as a non-US startup.

• Strong focus on applied artificial intelligence in healthcare to solve systemic inefficiencies. He frequently invests in startups using technology to reduce administrative burdens, such as minimizing wait times or helping clinicians focus on patient care. For instance, he championed a company using AI to streamline emergency room operations, allowing doctors and nurses to prioritize critical tasks.
• Interest in robotics and automation to drive operational productivity across various industries. He looks for companies using intelligent hardware or generative models to handle labor-intensive processes, ranging from government contract proposals to food supply chain management. A specific example includes his backing of a startup leveraging robots to consistently prepare ingredients in commercial kitchens.
• Deep commitment to social impact and global health equity. He regularly shares updates about a non-profit hospital he helped establish over a decade ago, indicating he values founders who are driven by a mission to improve the world. He also highlights efforts to mitigate climate change within the medical field, showing an appreciation for sustainability.
• Dedication to educating entrepreneurs on the mechanics of fundraising and company building. He shares practical advice for founders navigating the early stages, covering topics like equity distribution and how to handle the pre-seed phase when working alone. He emphasizes the importance of founders asking the right questions to properly vet potential venture capital partners.
• Preference for entering at the earliest stages of a company's lifecycle. He often notes his role as the first investor in a startup, signaling a willingness to back teams at the seed level before they have fully scaled. He highlighted this approach when discussing his early support for a platform assisting aging Americans and their caregivers with medication and health management.